Diabetes Mellitus Type II Clinical Trial
Official title:
Multicenter Research Study to Build a Repository That Will Allow Researchers to Study Chronic Diseases in the Population of Central Indiana
Blood samples and health information (e.g., age at diagnosis, test results) are collected for the purposes of genetic research. The blood samples are assigned a number and stored in a repository for safe keeping until they are needed for a research project. Participants are persons who are healthy (not having high blood pressure, diabetes, or high cholesterol levels) or persons who have Diabetes Mellitus Type II(T2D) and live in Indiana. Participants complete a questionnaire at the time the blood sample is drawn. Visits are repeated at 2 and 5 years after initial contact. Researchers apply to the Fairbanks Institute for use of the blood samples and health information minus participant names and contact information. Their research is required to be related to find genes or substances made by genes that may be involved in Diabetes Mellitus Type II with the purpose of improving the investigators understanding of the illness potentially leading to the development of new diagnostic tools for identifying the illness, new treatments,or preventative measures.
Study Aim:
The purpose of this study is to create an extensively annotated bio-repository platform for
hypothesis-driven research that will lead to advancements in the diagnosis, treatment and
prevention of diseases common to the population of Indiana. The second phase of this
research platform will be created by collecting blood samples from two groups of individuals
in the Central Indiana community, one with documented evidence of Diabetes Mellitus Type
II(T2D), and a second group of age, gender and ethnicity matched individuals without
clinical evidence of Diabetes. Each individual's blood sample will be linked to their
clinical, demographic and epidemiological information, gathered both retrospectively and
prospectively.
Recruitment:
This study will include 500 individuals with T2D (the T2D Group) and 500 individuals who are
age, gender, and ethnicity matched to the T2D Group, but without presentation of clinical
evidence of T2D (the Control Group). To reflect the growing representation of Hispanics in
Central Indiana, Hispanics will be overly recruited in both groups so that the study
population accurately reflects the general population of Central Indiana.
Follow-up:
As this is a prospective, longitudinal study, follow-up of study subjects is intended to
include two follow up visit and continue indefinitely, unless, of course, at any time,
consent for further follow-up is withdrawn by the subject. Follow-up will include visits at
2 and 5 years post initial contact and continuing access to the subject's medical record to
pursue data concerning changes in the subject's health. Subjects may be contacted by
telephone, mail or email every twelve months to ask if they wish to continue participation
in the study. The 2 and 5 year follow up visits mirror the initial visit.
The collected dataset (made up of the collected blood samples linked to clinical and
epidemiological information collected retrospectively and prospectively), will be used in
medical research to find genes, or gene products such as RNA or proteins that will help in
understanding the causes of disease and will guide the development of new treatments
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT02261545 -
The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient
|
Phase 4 | |
Completed |
NCT02028091 -
Diabetes Mellitus - A Diagnosis Trial by Means of Non Invasive Measurements
|
N/A | |
Completed |
NCT01684813 -
VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel
|
Phase 4 | |
Completed |
NCT01252524 -
Effect of Calcium Polycarbophil on Type II Diabetes Mellitus Control: a Randomized Double-blind Study
|
N/A | |
Recruiting |
NCT01311401 -
Predictors of Future Type 2 Diabetes Mellitus in Circassians Minority in Israel
|
N/A | |
Completed |
NCT00563225 -
20 Week Bridging Study in Type II DM
|
Phase 3 | |
Recruiting |
NCT01565096 -
Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy
|
Phase 4 | |
Completed |
NCT00151697 -
LANN-study: Lantus, Amaryl, Novorapid, Novomix Study
|
Phase 3 | |
Withdrawn |
NCT01453751 -
Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Type II Diabetes
|
N/A | |
Not yet recruiting |
NCT01775059 -
Collection of Performance Data From the Integrated Sensor and Infusion Set. TRIAL 4
|
N/A | |
Completed |
NCT01281098 -
Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.
|
Phase 2 | |
Completed |
NCT01669473 -
A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use
|
N/A | |
Completed |
NCT02036372 -
Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus
|
N/A | |
Completed |
NCT03258840 -
EPA Supplementation on Vascular Inflammation, and Gene Expression of PON2 in Patients With Type II Diabetes Mellitus
|
N/A | |
Completed |
NCT02144948 -
Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II
|
Phase 3 |